<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314986</url>
  </required_header>
  <id_info>
    <org_study_id>AR882-102</org_study_id>
    <nct_id>NCT04314986</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of AR882, a Potent Uricosuric Agent, in Healthy Adult Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthrosi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arthrosi Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess multiple ascending doses of AR882 in healthy adult males.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Actual">September 18, 2019</completion_date>
  <primary_completion_date type="Actual">September 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety profile of AR882 based on incidence of adverse events</measure>
    <time_frame>22 Days</time_frame>
    <description>Incidence of adverse events following multiple doses of AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety profile of AR882 based on incidence of abnormal laboratory findings</measure>
    <time_frame>22 Days</time_frame>
    <description>Incidence of abnormal laboratory findings following multiple doses of AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety profile of AR882 based on incidence of abnormal electrocardiogram findings</measure>
    <time_frame>22 Days</time_frame>
    <description>Incidence of abnormal electrocardiogram findings following multiple doses of AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety profile of AR882 based on incidence of abnormal vital signs findings</measure>
    <time_frame>22 Days</time_frame>
    <description>Incidence of abnormal vital signs findings following multiple doses of AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) for plasma AR882</measure>
    <time_frame>15 Days</time_frame>
    <description>Profile from plasma in terms of AUC following multiple doses of AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) for AR882</measure>
    <time_frame>15 Days</time_frame>
    <description>Profile from plasma in terms of Tmax following multiple doses of AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) for AR882</measure>
    <time_frame>15 Days</time_frame>
    <description>Profile from plasma in terms of Cmax following multiple doses of AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life (t1/2) for AR882</measure>
    <time_frame>15 Days</time_frame>
    <description>Profile from plasma in terms of t1/2 following multiple doses of AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount excreted (Ae) into urine for AR882</measure>
    <time_frame>15 Days</time_frame>
    <description>Profile from urine in terms of Ae following multiple doses of AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractional Excretion (FEUA) for AR882</measure>
    <time_frame>15 Days</time_frame>
    <description>Profile from urine in terms of FEUA following multiple doses of AR882</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD profile following multiple doses of AR882</measure>
    <time_frame>15 Days</time_frame>
    <description>Profile from serum uric acid concentrations over time</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>AR882 (Dose A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AR882 (Dose B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AR882 (Dose C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AR882 (Dose D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1: AR882 or placebo</intervention_name>
    <description>AR882 or matching placebo administered once daily for 10 days</description>
    <arm_group_label>AR882 (Dose A)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2: AR882 or placebo</intervention_name>
    <description>AR882 or matching placebo administered once daily for 10 days.</description>
    <arm_group_label>AR882 (Dose B)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 3: AR882 or placebo</intervention_name>
    <description>AR882 or matching placebo administered once daily for 10 days</description>
    <arm_group_label>AR882 (Dose C)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 4: AR882 or placebo</intervention_name>
    <description>AR882 or matching placebo administered once daily for 10 days</description>
    <arm_group_label>AR882 (Dose D)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening serum uric acid level ≥ 4.5 mg/dL (268 µmol/L) and &lt; 9 mg/dL (535 µmol/L)

          -  Body weight no less than 50 kg and body mass index (BMI) within the range of ≥18 and
             ≤33 kg/m2

          -  Must be free of any clinically significant disease that requires a physician's care
             and/or would interfere with study evaluations or procedures

        Exclusion Criteria:

          -  Malignancy within 5 years, except for successfully treated basal or squamous cell
             carcinoma of the skin

          -  History of cardiac abnormalities

          -  History and/or presence of drug addiction or excessive use of alcohol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nucleus Network Pty, Ltd.</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

